Dulaglutide for the treatment of type 2 diabetes

Drugs of Today

Volumn 50, Issue 4, 2014, Pages 277-289

  Amblee, A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dulaglutide; Glucagon like peptide 1 (GLP 1) analogues; Type 2 diabetes

Indexed keywords

DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SITAGLIPTIN;

ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; BREAST CANCER; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; DRUG APPROVAL; DRUG DELIVERY DEVICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HALLUCINATION; HEADACHE; HEALTH STATUS; HEART ATRIUM FLUTTER; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INJECTION SITE IRRITATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OUTCOMES RESEARCH; PANCREATITIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PULSE RATE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; STOMACH EMPTYING; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

DULAGLUTIDE; GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ANALOGUES; TYPE 2 DIABETES;

ANIMALS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS;

EID: 84899709251     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.4.2132740     Document Type: Article

References (34)

1. Albert, N.M. Improving medication adherence in chronic cardiovascular disease. Crit Care Nurse 2008, 28(5): 54-64.
2. Sokol, M.C., McGuigan, K.A., Verbrugge, R.R., Epstein, R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43(6): 521-30. (Pubitemid 40847288)
3. Asche, C., LaFleur, J., Conner, C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011, 33(1): 74-109.
4. Nasseh, K., Frazee, S.G., Visaria, J., Vlahiotis, A., Tian, Y. Cost of medication nonadherence associated with diabetes, hypertension, and dyslipidemia. Am J Pharm Benefits 2012, 4(2): e41-7.
5. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6): 1364-79.
6. Hansen, K.B., Knop, F.K., Holst, J.J., Vilsboll, T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract 2009, 63(8): 1154-60.
7. Picha, K.M., Cunningham, M.R., Drucker, D.J. et al. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes 2008, 57(7): 1926-34.
8. Glaesner, W., Vick, A.M., Millican, R. et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010, 26(4): 287-96.
9. Barrington, P., Chien, J.Y., Tibaldi, F., Showalter, H.D., Schneck, K., Ellis, B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011, 13(5): 434-8.
10. Chien, J.Y., Cui, S., Chaudhary, A., Loghin, C. LY2189265, a long-acting glucagon-like peptide-1 analog does not affect gastric emptying of acetaminophen after multiple dosing in healthy subjects. Diabetes 2010, 59: A164.
11. Barrington, P., Chien, J.Y., Showalter, H.D. et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13(5): 426-33.
12. Grunberger, G., Chang, A., Garcia Soria, G., Botros, F.T., Bsharat, R., Milicevic, Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012, 29(10): 1260-7.
13. Umpierrez, G.E., Blevins, T., Rosenstock, J., Cheng, C., Anderson, J.H., Bastyr, E.J., 3rd, Group, E.G.O.S. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011, 13(5): 418-25.
14. Bastyr, E.J., 3rd, Noriega, J., Botros, F.T. et al. The impact of Hispanic ethnicity on the response to LY2189265 (GLP-1 analog) treatment of uncontrolled type 2 diabetes mellitus (T2DM) patients: An EGO Study analysis. 19th Annu Meet Clin Congr Amer Assoc Clin Encocrinologists (April 21-25, Boston) 2010, Abst 242.
15. Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., Scism-Bacon, J., Lakshmanan, M. Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1). 49th Annu Meet Eur Assoc Study Diabetes (EASD) (September 23-27, Barcelona) 2013, Abst 919.
16. Van Brunt, K., Reaney, M., Yu, M., Lakshmanan, M., Curtis, B., Mitchell, B. Patient-reported outcomes with dulaglutide, exenatide, or placebo (AWARD-1). 49th Annu Meet Eur Assoc Study Diabetes (EASD) (September 23-27, Barcelona) 2013, Abst 885.
17. Povedano, S.T., Umpierrez, G., Manghi, F.P., Shurzinske, L., Pechtner, V. Efficacy and safety of dulaglutide vs metformin in type 2 diabetes (AWARD-3). 49th Annu Meet Eur Assoc Study Diabetes (EASD) (September 23-27, Barcelona) 2013, Abst 4.
18. Reaney, M., Mitchell, B.D., Wang, P., Pechtner, V., Curtis, B.H., Van Brunt, K. Patient-reported outcomes with dulaglutide vs. metformin (AWARD-3). 73rd Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 21-25, Chicago) 2013, Abst 1027-P.
19. Nauck, M.A., Weinstock, R.S., Umpierrez, G., Guerci, B., Boleyn, K., Skrivanek, Z., Milicevic, Z. Efficacy and safety of dulaglutide vs. sitagliptin after 52 weeks in type 2 diabetes (AWARD-5). 49th Annu Meet Eur Assoc Study Diabetes (EASD) (September 23-27, Barcelona) 2013, Abst 921.
20. Guerci, B., Weinstock, R.S., Umpierrez, G., Nauck, M.A., Boleyn, K., Skrivanek, Z., Milicevic, Z. Safety and efficacy of dulaglutide vs sitagliptin after 104 weeks in type 2 diabetes (AWARDS). 49th Annu Meet Eur Assoc Study Diabetes (EASD) (September 23-27, Barcelona) 2013, Abst 920.
21. A randomized, open-label, parallel-arm, noninferiority comparison of the effects of two doses of LY2189265 and insulin glargine on glycemic control in patients with type 2 diabetes on stable doses of metformin and glimepiride (AWARD-2) (NCT010/5282). ClinicalTrials.gov Web site, Accessed March 19, 2014.
22. Lilly announces positive results of phase III trials of dulaglutide in type 2 diabetes [news release]. Eli Lilly and Company, April 16, 2013. https://investor.lilly.com/releasedetail.cfm?ReleaseID=756743. Accessed April 22, 2014.
23. The impact of LY2189265 versus insulin glargine in combination with insulin lispro for the treatment to target of type 2 diabetes mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4) (NCT01191268). ClinicalTrials.gov Web site, Accessed March 19, 2014.
24. A randomized, open-label, parallel-arm study comparing the effect of once-weekly dulaglutide with once-daily liraglutide in patients with type 2 diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6) (NCT01624259). ClinicalTrials.gov Web site, Accessed March 19, 2014.
25. A randomized, open-label, parallel-arm study comparing the effect of once-weekly dulaglutide with insulin glargine on glycemic control in patients with type 2 diabetes and moderate or severe chronic kidney disease (AWARD-7 Assessment of Weekly AdministRation of LY2189265 in Diabetes-7) (NCT01621178). ClinicalTrials.gov Web site, Accessed March 19, 2014.
26. A randomized, parallel-arm, double-blinded study comparing the effect of once-weekly dulaglutide with placebo in patients with type 2 diabetes mellitus on sulfonylurea therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8) (NCT01769378). ClinicalTrials.gov Web site, Accessed March 19, 2014.
27. The efficacy and safety of once-weekly, subcutaneous dulaglutide compared to once-daily insulin glargine in patients with type 2 diabetes mellitus on metformin and/or a sulfonylurea (NCT01648582). ClinicalTrials.gov Web site, Accessed March 19, 2014.
28. Lilly Diabetes presents phase II blood pressure and heart rate data on investigational GLP-1 analog candidate, dulaglutide, in patients with type 2 diabetes at the 27th American Society of Hypertension Scientific Meeting [news release]. Eli Lilly and Company, May 22, 2012. https://investor.lilly.com/ releasedetail.cfm?ReleaseID=675659. Accessed November 18, 2014.
29. Loghin, C., Chien, J.Y., Cui, S., Geiser, J., Hodgson, T., Chaudhary, A. LY2189265, a long-acting GLP-1 analog, does not prolong QTc interval in healthy subjects at supratherapeutic doses. 71st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 1089-P.
30. Weinstock, R.S., Umpierrez, G.E., Guerci, B., Nauck, M.A., Boleyn, K.L., Skrivanek, Z., Milicevic, Z. Safety and efficacy of dulaglutide vs. sitagliptin after 104 weeks in type 2 diabetes (AWARD-5). 73rd Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 21-25, Chicago) 2013, Abst 1004-P.
31. Buse, J.B., Rosenstock, J., Sesti, G. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374(9683): 39-47.
32. Drucker, D.J., Buse, J.B., Taylor, K. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372(9645): 1240-50.
33. Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E. Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 2014, 103(2): 269-75.
34. Eli Lilly submits GLP-1 dulaglutide to FDA and unveils injection device. diaTribe, November 19, 2013. http://diatribe.us/issues/59/new-now-next/5. Accessed April 11, 2014.